Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Research & Development (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Research & Development for 5 consecutive years, with $17.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 6.28% year-over-year to $17.0 million, compared with a TTM value of $69.5 million through Dec 2025, down 1.16%, and an annual FY2025 reading of $69.5 million, down 1.16% over the prior year.
  • Research & Development was $17.0 million for Q4 2025 at Aligos Therapeutics, down from $23.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $31.7 million in Q1 2022 and bottomed at $14.0 million in Q2 2025.
  • Average Research & Development over 5 years is $20.1 million, with a median of $18.0 million recorded in 2022.
  • The sharpest move saw Research & Development crashed 42.75% in 2023, then skyrocketed 42.7% in 2025.
  • Year by year, Research & Development stood at $28.6 million in 2021, then tumbled by 33.21% to $19.1 million in 2022, then increased by 16.53% to $22.3 million in 2023, then dropped by 27.97% to $16.0 million in 2024, then rose by 6.28% to $17.0 million in 2025.
  • Business Quant data shows Research & Development for ALGS at $17.0 million in Q4 2025, $23.9 million in Q3 2025, and $14.0 million in Q2 2025.